You are here

Tolvaptan

Otsuka's tolvaptan gets priority review at FDA

Pharma Times, UK

Mon, 04/15/13 - 09:36 am

autosomal dominant polycystic kidney disease

FDA Agrees to Priority Review for First ADPKD Therapy

Monthly Prescribing Reference

Sat, 04/13/13 - 12:15 pm

autosomal dominant polycystic kidney disease

Otsuka's Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Tolvaptan, Meets Primary Endpoint in a Phase III Clinical Trial

Business Wire

Sun, 11/4/12 - 10:54 am

autosomal dominant polycystic kidney disease